# Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

> **NCT07672769** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Faron Pharmaceuticals Ltd** · enrollment: 90 (estimated)

## Conditions studied

- Higher Risk Myelodysplastic Syndromes

## Interventions

- **DRUG:** bexmarilimab (1mg/kg)
- **DRUG:** azacitidine
- **DRUG:** Placebo
- **DRUG:** bexmarilimab (3mg/kg)

## Key facts

- **NCT ID:** NCT07672769
- **Lead sponsor:** Faron Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07672769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07672769, "Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07672769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*